bioRxiv · 10.1101/2021.11.14.468537
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2
Abstract
Inhibitors of Bromodomain and Extra-terminal domain (BET) proteins are possible anti-SARS-CoV-2 prophylactics as they downregulate angiotensin-converting enzyme 2 (ACE2). Here, we show that BET proteins should not be inactivated therapeutically as they are critical antiviral factors at the post-entry level. Knockouts of BRD3 or BRD4 in cells overexpressing ACE2 exacerbate SARS-CoV-2 infection; the same is observed when cells with endogenous ACE2 expression are treated with BET inhibitors during infection, and not before. Viral replication and mortality are also enhanced in BET inhibitor-treated mice overexpressing ACE2. BET inactivation suppresses interferon production induced by SARS-CoV-2, a process phenocopied by the envelope (E) protein previously identified as a possible "histone mimetic." E protein, in an acetylated form, directly binds the second bromodomain of BRD4. Our data support a model where SARS-CoV-2 E protein evolved to antagonize interferon responses via BET protein inhibition; this neutralization should not be further enhanced with BET inhibitor treatment.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chen, I., Longbotham, J. E., McMahon, S., Suryawanshi, R., Carlson-Stevermer, J., Gupta, M., Zhang, M. Y., Soveg, F. W., Hayashi, J. M., Taha, T. Y., Lam, V. L., Li, Y., Yu, Z., Titus, E. W., Diallo, A., Oki, J., Holden, K., QCRG Structural Biology Consortium,, Krogan, N. J., Fijimori, D. G., Ott, M.. 2021-11-15. Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2. https://doi.org/10.1101/2021.11.14.468537
Cite the original work for its findings. Save a collection to share your selection of sources.